These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22512284)

  • 1. 14-3-3 zeta as novel molecular target for cancer therapy.
    Matta A; Siu KW; Ralhan R
    Expert Opin Ther Targets; 2012 May; 16(5):515-23. PubMed ID: 22512284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14-3-3ζ as a prognostic marker and therapeutic target for cancer.
    Neal CL; Yu D
    Expert Opin Ther Targets; 2010 Dec; 14(12):1343-54. PubMed ID: 21058923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival.
    Murata T; Takayama K; Urano T; Fujimura T; Ashikari D; Obinata D; Horie-Inoue K; Takahashi S; Ouchi Y; Homma Y; Inoue S
    Clin Cancer Res; 2012 Oct; 18(20):5617-27. PubMed ID: 22904106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 14-3-3zeta associated protein networks in oral cancer.
    Matta A; Masui O; Siu KW; Ralhan R
    Proteomics; 2016 Apr; 16(7):1079-89. PubMed ID: 26857332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta.
    Chatterjee D; Goldman M; Braastad CD; Darnowski J; Wyche JH; Pantazis P; Goodglick L
    Int J Oncol; 2004 Aug; 25(2):503-9. PubMed ID: 15254750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the mTOR pathway as a target in cancer therapy.
    Gentzler RD; Altman JK; Platanias LC
    Expert Opin Ther Targets; 2012 May; 16(5):481-9. PubMed ID: 22494490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting syndecans: a promising strategy for the treatment of cancer.
    Choi S; Kang DH; Oh ES
    Expert Opin Ther Targets; 2013 Jun; 17(6):695-705. PubMed ID: 23421390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
    Perego P; Cossa G; Zuco V; Zunino F
    Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
    Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A; Bernal-Mizrachi L; Vertino P; Sun SY; Chen J; Munshi N; Fu H; Kowalski J; Boise LH; Lonial S
    Leukemia; 2018 Mar; 32(3):744-751. PubMed ID: 28924240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
    Schwock J; Dhani N; Hedley DW
    Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways.
    Porter GW; Khuri FR; Fu H
    Semin Cancer Biol; 2006 Jun; 16(3):193-202. PubMed ID: 16697216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel targeted therapies for the treatment of penile cancer.
    Agarwal G; Gupta S; Spiess PE
    Expert Opin Drug Discov; 2014 Aug; 9(8):959-68. PubMed ID: 24896220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
    Alimbetov D; Askarova S; Umbayev B; Davis T; Kipling D
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cells: the development of new cancer therapeutics.
    Scatena R; Bottoni P; Pontoglio A; Giardina B
    Expert Opin Biol Ther; 2011 Jul; 11(7):875-92. PubMed ID: 21463158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in cancer therapy: an update.
    Papeo G; Casale E; Montagnoli A; Cirla A
    Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oncoprotein EPS8: a new target for anticancer therapy.
    Li YH; Xue TY; He YZ; Du JW
    Future Oncol; 2013 Oct; 9(10):1587-94. PubMed ID: 24106906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer.
    Fendrich V; Lauth M
    Expert Opin Ther Targets; 2014 Nov; 18(11):1277-83. PubMed ID: 25078025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.